secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001213900-25-040809
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics Q1 2025 net loss $11.9M; TARA-002 100% CR in BCG-Unresponsive cohort
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments total $157.5M as of Mar 31, 2025; expected to fund operations into 2027.
- TARA-002 in BCG-Unresponsive NMIBC: 100% complete response (CR) at any time (5/5), 67% CR at 12 months (2/3) as of Apr 16, 2025.
- Interim results from ~25 six-month evaluable BCG-Unresponsive patients expected by end of 2025; THRIVE-3 trial of IV Choline Chloride to start Q3 2025.
- Appointed Leonardo Viana Nicacio, M.D., as CMO and Shane Williams, Ph.D., as VP, Head of HR/Chief People Officer in April 2025.
- Net loss $11.9M ($0.29/sh) vs $11.1M ($0.97/sh) in Q1 2024; R&D expenses rose to $9.1M from $7.7M, G&A to $5.0M from $4.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025040809/0001213900-25-040809-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390025040809/ea0240929-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-040809

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer